A live attenuated SARS-CoV-2 vaccine constructed by dual inactivation of NSP16 and ORF3a
This work was supported by National Key Research and Development Program of China (2021YFC0866100, 2023YFC3041600, and 2023YFE0203400), Hong Kong Health and Medical Research Fund (COVID190114, CID-HKU1-9, and 23220712), Hong Kong Research Grants Council (C7142-20GF and T11-709/21-N), Hong Kong Innovation and Technology Commission grant (MHP/128/22), Guangzhou Laboratory (EKPG22-01) and Health@InnoHK (CVVT). Funding sources had no role in the writing of the manuscript or the decision to submit it for publication.
Authors
- Tao Ni (ORCID: https://orcid.org/0000-0001-7268-0306)
- Pak‐Hin Hinson Cheung (ORCID: https://orcid.org/0000-0003-3682-7571)
- Victor Sebastien Gray (ORCID: https://orcid.org/0000-0002-1687-4576)
- Kaiming Tang (ORCID: https://orcid.org/0000-0001-7310-6744)
- Chon Phin Ong (ORCID: https://orcid.org/0000-0001-6137-7926)
- Dong‐Yan Jin (ORCID: https://orcid.org/0000-0002-2778-3530)
- Hehe Cao
- Hongzhuo Zhang
- Peng Luo (ORCID: https://orcid.org/0000-0002-8215-2045)
- Guang Sheng Ling (ORCID: https://orcid.org/0000-0002-6347-0005)
- Zi‐Wei Ye (ORCID: https://orcid.org/0000-0002-6446-4299)
- Weixin Li (ORCID: https://orcid.org/0000-0002-4303-4134)
- Junjue Wang (ORCID: https://orcid.org/0009-0009-9774-4965)
- Ming Zhang (ORCID: https://orcid.org/0009-0005-0741-7997)
- Chi Ping Chan
- Shuofeng Yuan
- Yuntao Zhang (ORCID: https://orcid.org/0009-0006-9134-5582)
Institutions
- National Vaccine and Serum Institute (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- EBioMedicine
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1016/j.ebiom.2025.105662
- Citations
- 3
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 4.19
Funders
- Innovation and Technology Commission
- Health and Medical Research Fund
- National Key Research and Development Program of China